Summary
1 - MECHANISM OF ACTION
Adalimumab (Humira®) is a recombinant human monoclonal antibody that inhibits TNF-α.
TNF-alpha, a molecule that promotes inflammation, plays a key role in chronic inflammatory diseases. Humira® is an antibody that binds specifically to TNF-α, which stops the molecule from binding to its natural receptor. Humira® therefore stops TNF-α from exerting its anti-inflammatory effect. Although in principle Humira® is only mildly immunogenic, anti-adalimumab antibodies are observed in 8 to 10% of patients [1].
×
N.B. : This limited content is for the general public. If you are a health professional, click here to register for free and gain access to a dedicated deeper content.
If you already have an account, log in!
Therapeutics in Dermatology, Fondation René Touraine © 2001-2014
